Indexed with PubMed and Science Citation Index (E) 
Users online: 2984 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (125 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article
   Article Figures

 Article Access Statistics
    PDF Downloaded242    
    Comments [Add]    
    Cited by others 12    

Recommend this journal


Year : 2006  |  Volume : 72  |  Issue : 4  |  Page : 307-309

Fixed drug eruption and generalised erythema following etoricoxib

Department of Dermatology, St. John's Medical College Hospital, Bangalore, India

Correspondence Address:
Mary Augustine
Department of Dermatology, St. John's Medical College Hospital, Sarjapur Road, Bangalore - 560 034, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.26732

Rights and Permissions

How to cite this article:
Augustine M, Sharma P, Stephen J, Jayaseelan E. Fixed drug eruption and generalised erythema following etoricoxib. Indian J Dermatol Venereol Leprol 2006;72:307-9

How to cite this URL:
Augustine M, Sharma P, Stephen J, Jayaseelan E. Fixed drug eruption and generalised erythema following etoricoxib. Indian J Dermatol Venereol Leprol [serial online] 2006 [cited 2020 Dec 5];72:307-9. Available from:


Non steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications - both by prescription and over the counter. The newer NSAIDs, inhibitors of the cyclo-oxygenase enzyme-2 (COX-2 inhibitors), are fast becoming the drugs of first choice in the treatment of acute pain, chronic pain and most rheumatic conditions. These compounds blunt prostaglandin production through inhibition of cyclooxygenase-2 (COX-2) while sparing cyclooxygenase-1 (COX-1), and have been shown to cause significantly fewer serious gastrointestinal adverse events such as ulceration and bleeding, than the nonselective NSAIDs.[1] Etoricoxib, one of the newer COX-2 inhibitors, has enhanced biochemical COX-2 selectivity over that of the other drugs in this category: rofecoxib and celecoxib.[2] Though, adverse cutaneous effects to celecoxib and rofecoxib have been reported, there has been no report of cutaneous side effects to etoricoxib so far. We report a case of fixed drug eruption and generalized erythema occurring simultaneously following etoricoxib.

A 38-year-old female, doctor by profession, developed a 1.5 cm size, well circumscribed, round, erythematous patch on the right forearm, 3 days following ingestion of etoricoxib that was prescribed for bursitis of right knee. In the next few days, the center of the patch developed a blister and necrosis which later healed with residual hyperpigmentation. She had taken various NSAIDs many times in the past and rofecoxib on more than two occasions. Celecoxib had been taken at least for one week, once, about two years back. Etoricoxib was taken once, for one week, 5 months back. There were no adverse effects to any of the drugs previously. Therefore the possibility of a drug eruption was not thought of and a diagnosis of 'insect bite reaction' was considered. Two months after the lesion healed, the patient took a single tablet of etoricoxib again. She noticed erythema, itching and burning over the old lesion within two hours [Figure - 1]. In addition, over the next three to four hours she developed generalized itching and burning sensation followed by intense erythema all over the body. Nikolsky's sign was negative. There was no mucosal involvement. The patient had neither fever nor other constitutional symptoms. No systemic abnormalities were found on physical and routine laboratory examination. A histopathological examination was not performed as the patient did not consent for skin biopsy.

A drug reaction was diagnosed and systemic steroids were administered. Though most of the symptoms and signs gradually subsided in ten days, mild acral dusky erythema persisted for 4 weeks. The lesion over the right forearm developed a small blister and healed with a larger area of residual pigmentation. The erythema over the rest of the body subsided leaving behind no residual pigmentation.

Since a reliable positive oral re-challenge had already taken place, although inadvertently; further confirmatory tests were not carried out immediately. However, a patch test with etoricoxib 10% in petrolatum was done six months later. Erythema and edema which was double the size of the old patch was seen within eight hours, over the healed FDE lesion, whereas the non-lesional control area did not react.

Fixed drug eruption (FDE) characteristically presents as a round, sharply circumscribed, pruritic or burning, edematous patch with violaceous or dusky erythema.[3] Vesicles or bullae may develop. It heals leaving a hyper-pigmented patch and recurs at the same site on drug rechallenge. The residual pigmentation and recurrence of lesion at the same site are the typical features of FDE. Additional lesions may develop with drug rechallenge. Although a histopathological examination was not performed in our patient, the typical round patch with bulla, the residual pigmentation on healing and the recurrence of the rash at the same site, support a diagnosis of fixed drug eruption. The severity of the patch test reaction confirms etoricoxib as the causative drug.

An unusual feature of this case, however, was the occurrence of two different types of cutaneous adverse reactions simultaneously to the same drug. Clinically the patient had a FDE and a generalized erythematous rash. Although very rare, occurrence of more than one type of cutaneous reactions to the same drug has been reported.[4] Most of the known adverse cutaneous reactions to coxibs have been attributed to either celecoxib or rofecoxib. They include: urticaria/angioedema (by far the most common), Sweet's syndrome, vasculitis, erythema multiforme, Stevens Johnson syndrome, toxic epidermal necrolysis (TEN) and maculopapular rash.[5],[6],[7] To the best of our knowledge cutaneous reactions to etoricoxib have not been reported so far.

The NSAIDs and coxibs with a sulfonamide structure (celecoxib and valdecoxib) could possibly cross react with sulfonamides.[8] The sulfonamide-type reactions (erythema multiforme, Stevens Johnson syndrome, toxic epidermal necrolysis (TEN) and maculopapular rash) were found to be twice as common with celecoxib as with rofecoxib.[5] The pathogenesis of these reactions is likely to be the same as for sulfonamide induced reactions - T cell mediated type IV hypersensitivity reaction. However, Shapiro et al in their study on the safety of celecoxib in 28 patients with a history of sulfonamide allergy found cross reactivity between celecoxib and sulfonamides to be low.[5]

The coxibs have generally been found to be safe even in patients allergic to the classic NSAIDs. Sanchez-Borges et al , in their review of cutaneous reactions to selective COX-2 inhibitors, reported that, among patients previously exhibiting urticaria or angioedema triggered by classic NSAIDs, only 1.6% developed urticaria or angioedema to rofecoxib and 11.2% to celecoxib.[5] However, in the present case, the patient had been tolerating various NSAIDs in the past but reacted to a coxib.

As the patient had taken rofecoxib on more than two occasions, with no side effects, it appears that there may not necessarily be cross reactivity between different coxibs.

To conclude, cutaneous adverse reactions to coxibs continue to be reported. Although these drugs are considered safer in individuals sensitive to other NSAIDs, this case suggests that the reverse could also be true.

  References Top

1.Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.  Back to cited text no. 1    
2.Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002;62:2637-51;discussion 2652-3.   Back to cited text no. 2  [PUBMED]  
3.Korkij W, Soltani K. Fixed drug eruption: A brief review. Arch Dermatol 1984;120:520-4.   Back to cited text no. 3  [PUBMED]  
4.Gupta PK, Luniya AK, Gupta NK, Tiwari ML. Coexistence of fixed drug eruptions and Stevens Johnson syndrome due to thiacetazone in a patient of pulmonary tuberculosis. Indian J Chest Dis Allied Sci 1983;25:152-4.  Back to cited text no. 4  [PUBMED]  
5.Sαnchez BM, Capriles HA, Caballero FF. Adverse Reactions to Selective Cyclooxygenase-2 Inhibitors (Coxibs). Am J Ther 2004;11:494-500.  Back to cited text no. 5    
6.Fye KH, Crowley E, Berger TG, Le Boit PE, Connolly MK. Celecoxib-induced Sweet's syndrome. J Am Acad Dermatol 2001;45:300-2.  Back to cited text no. 6    
7.Schneider F, Meziani F, Chartier C, Alt M, Jaeger A. Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852-3  Back to cited text no. 7    
8.Sarkar R, Kaur C, Kanwar AJ. Extensive fixed drug eruption to nimesulide with cross-sensitivity to sulfonamides in a child. Pediatr Dermatol 2002;19:553-4.  Back to cited text no. 8    


[Figure - 1]

This article has been cited by
1 Fixed Drug Eruption Due to Etoricoxib in a Patient With Tolerance to Celecoxib: The Value of Patch Testing
E. Gómez de la Fuente,A. Pampín Franco,D. Caro Gutiérrez,J.L. López Estebaranz
Actas Dermo-Sifiliográficas (English Edition). 2014;
[Pubmed] | [DOI]
2 An update of fixed drug eruptions in Singapore
Y.K. Heng,Y.W. Yew,D.S.Y. Lim,Y.L. Lim
Journal of the European Academy of Dermatology and Venereology. 2014; : n/a
[Pubmed] | [DOI]
3 Fixed drug eruption due to etoricoxibe – A case report
J. Antunes,S. Prates,P. Leiria-Pinto
Allergologia et Immunopathologia. 2013;
[Pubmed] | [DOI]
4 Etoricoxib-induced toxic epidermal necrolysis
Roy Moutran,Ismaël Maatouk,Josaine Hélou
International Journal of Dermatology. 2013; : n/a
[Pubmed] | [DOI]
5 Exantema fijo medicamentoso por etoricoxib con tolerancia a celecoxib. Utilidad de las pruebas epicutáneas
E. Gómez de la Fuente,A. Pampín Franco,D. Caro Gutiérrez,J.L. López Estebaranz
Actas Dermo-Sifiliográficas. 2013;
[Pubmed] | [DOI]
6 Unverträglichkeitsreaktionen auf Etoricoxib
Gerda Wurpts,Hans F. Merk
Allergo Journal. 2012; 21(5): 302
[Pubmed] | [DOI]
7 Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib
Vanessa Ponce, Francisco Muñoz-Bellido, Esther Moreno, Elena Laffond, Amanda González, Ignacio Dávila
Contact Dermatitis. 2012; 66(2): 107
[VIEW] | [DOI]
8 Fixed drug eruption caused by etoricoxib - 2 cases confirmed by patch testing
Pedro Andrade, Margarida Gonçalo
Contact Dermatitis. 2011; 64(2): 118
[VIEW] | [DOI]
9 Etoricoxib-induced fixed drug eruption with positive lesional patch tests
Ana Maria Calistru, Ana Paula Cunha, Ana Nogueira, Filomena Azevedo
Cutaneous and Ocular Toxicology. 2011; 30(2): 154
[VIEW] | [DOI]
10 Bullous fixed drug eruption to etoricoxib - Further evidence of intraepidermal CD8+ T cell involvement
Duarte, A.F., Correia, O., Azevedo, R., Palmares, M.D.C., Delgado, L.
European Journal of Dermatology. 2010; 20(2): 236-238
11 Anti-inflammatory and antipyretic analgesics and drugs used in gout
Aronson, J.K.
Side Effects of Drugs Annual. 2009; 31: 181-215
12 Selective immediate hypersensitivity to etoricoxib
Venturini Díaz, M., San Juan De La Parra, S., Segura Arazuri, N.
Journal of Investigational Allergology and Clinical Immunology. 2008; 18(6): 485-487


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow